These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36781142)

  • 1. Unblinding and demand characteristics in the treatment of depression.
    Goodwin GM; Croal M; Marwood L; Malievskaia E
    J Affect Disord; 2023 May; 328():1-5. PubMed ID: 36781142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Marson AG; Nevitt SJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Weston J; Singh J; Marson AG
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010682. PubMed ID: 25464360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
    Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI
    J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine and other glutamate receptor modulators for depression in adults.
    Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoxetine versus other types of pharmacotherapy for depression.
    Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
    Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.
    Mikocka-Walus A; Prady SL; Pollok J; Esterman AJ; Gordon AL; Knowles S; Andrews JM
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012680. PubMed ID: 30977111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxetine versus other anti-depressive agents for depression.
    Purgato M; Papola D; Gastaldon C; Trespidi C; Magni LR; Rizzo C; Furukawa TA; Watanabe N; Cipriani A; Barbui C
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD006531. PubMed ID: 24696195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
    McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?
    Feys F; Bekkering GE; Singh K; Devroey D
    Syst Rev; 2014 Feb; 3():14. PubMed ID: 24555576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressants for the treatment of depression in people with cancer.
    Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011006. PubMed ID: 29683474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressants for treating depression in dementia.
    Dudas R; Malouf R; McCleery J; Dening T
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD003944. PubMed ID: 30168578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
    Goodwin GM; Aaronson ST; Alvarez O; Atli M; Bennett JC; Croal M; DeBattista C; Dunlop BW; Feifel D; Hellerstein DJ; Husain MI; Kelly JR; Lennard-Jones MR; Licht RW; Marwood L; Mistry S; Páleníček T; Redjep O; Repantis D; Schoevers RA; Septimus B; Simmons HJ; Soares JC; Somers M; Stansfield SC; Stuart JR; Tadley HH; Thiara NK; Tsai J; Wahba M; Williams S; Winzer RI; Young AH; Young MB; Zisook S; Malievskaia E
    J Affect Disord; 2023 Apr; 327():120-127. PubMed ID: 36740140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressants using active placebos.
    Moncrieff J; Wessely S; Hardy R
    Cochrane Database Syst Rev; 2001; (2):CD003012. PubMed ID: 11406060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
    Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
    Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications for blinding in clinical trials with THC-containing cannabinoids based on the CANNA-TICS trial.
    Müller-Vahl KR; Jakubovski E; Fremer C; Lenz-Ziegenbein M; Großhennig A; Klages C; Koch A; Haas M; Pisarenko A
    Front Neurosci; 2022; 16():793703. PubMed ID: 36213751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expectancy in placebo-controlled trials of psychedelics: if so, so what?
    Butler M; Jelen L; Rucker J
    Psychopharmacology (Berl); 2022 Oct; 239(10):3047-3055. PubMed ID: 36063208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.